The Brandex Illusion: A Case Study on the Power of Comprehensive Data Analysis – (Brand Management (87)
Opening Scene: 1st July 2022
It was a quiet afternoon at the headquarters of V & V Pharmaceuticals, a day after the Qr.1 closing.
Mohan Dhawan, the Chief Marketing Officer, sat at his desk studying a report from the supply chain team. The numbers made him pause.
He checked them again.
Brandex inventory across warehouses and Carry-and-Forward agents had reached 6.7 months of stock.
He leaned back slowly and calculated the value.
Nearly ₹2.3 crores of inventory.
Just three months earlier, the marketing team had been celebrating the brand’s impressive growth. Now Mohan wondered whether that growth had been real.
Across the corridor sat Mala Gupte, the brand manager responsible for Brandex. Only a few months ago, she believed she had created a winning strategy.
Now the numbers were beginning to tell a different story.
Company Background
V & V Pharmaceuticals had built a reputation as a professionally managed company. The leadership believed that brand managers should have the freedom to make decisions and experiment with ideas.
This philosophy encouraged initiative and speed.
In January 2015, the company introduced Brandex, a new-generation antiemetic used to prevent nausea and vomiting. The market was competitive, but the product began gaining acceptance among doctors.
Within a few years, Brandex appeared poised to become a strong player in its category.
By 2022, the brand was managed by Mala Gupte, an energetic and ambitious brand manager.
The Promotion Decision
Mala believed Brandex needed an extra push to accelerate growth.
After discussions with the sales team, she proposed a trade promotion:
Buy five strips of Brandex and get one strip free.
Her reasoning seemed logical. Retailers and distributors would increase their purchases to benefit from the offer. More stock in pharmacies would increase visibility and encourage doctors to prescribe the brand.
The proposal was approved.
Early Signs of Success
Soon after the promotion began, shop audit numbers from the agency RRSR (Royal Retail Sales Research) started showing impressive growth.
The numbers excited the marketing team.
Mala felt proud of her decision.
During the Production Planning and Material Control (PPMC) meeting she made a confident request.
“To meet the growing demand,” she said, “we should increase production by 30 percent for May, June, and July.”
The production team noted the request.
But one person in the room was cautious.
Mohan Dhawan quietly said, “It may be too early to celebrate. Please review the decision to increase production.”
Mala disagreed. The numbers seemed clear. To her, the brand was growing rapidly.
A Conflicting Signal
In April 2022, the Prescription Audit Research Center (PARC) presented its four-monthly analysis.
The findings surprised the marketing team.
The report showed a sharp decline in Brandex prescriptions.
Mala dismissed the findings. “Bullshit,” she confided to her close friend Nutan. She believed prescription audits were often unreliable.
“Our sales numbers clearly show growth,” she argued.
Mohan Dhawan did not debate the point. Instead, he suggested that Mala visit major markets across the country.
“Let us see what doctors are actually prescribing,” he said.
The Market Reality
Over the next few weeks, Mala travelled across eight metro cities, four semi-metro towns, and many two- and three-tier towns.
She met doctors, pharmacists, and distributors.
Gradually, a pattern became visible.
More doctors were prescribing Compex, the main competitor of Brandex.
In many clinics, Compex prescriptions were rising steadily.
The reality in the market did not match the excitement created by the earlier sales numbers.
The Inventory Shock
Back at headquarters, Mala studied the company’s MIS reports more closely.
Sales after June 2022 began declining sharply.
The earlier growth had largely been caused by channel stocking. Retailers had purchased extra stock to take advantage of the bonus scheme.
But prescription demand had not increased.
Meanwhile, warehouses were filling with unsold inventory.
The promotion had pushed products into the supply chain but had not created real demand.
The Need for Comprehensive Data Analysis
The Brandex episode highlighted the importance of Comprehensive Data Analysis (CDA).
Managers often rely on a single indicator, such as sales growth. However, a brand’s true health can be understood only when multiple data sources are examined together.
When analyzed together, these sources provide a clearer understanding of brand performance.
Viewed together, the data revealed the real situation.
Visual Framework: The CDA Lens
A useful way to visualize CDA is to imagine four lenses through which a brand must be examined.
Doctor Lens – Prescription audit Market Lens – Shop audit Company Lens – Internal sales data Supply Chain Lens – Inventory levels
When all four lenses show the same direction, managers can trust the trend.
When the signals contradict each other, a deeper investigation is required.
Brandex had entered the Illusion of Growth quadrant.
Sales were rising, but prescriptions were falling.
The Decision Challenge
The leadership team now faced several questions.
Should the company stop the promotion immediately? Should production be reduced sharply? Should the marketing team investigate why doctors were shifting to the competitor?
More importantly, how could the company ensure that such situations would not occur again?
Case Epilogue
Three months later, the leadership team of V & V Pharmaceuticals took corrective action.
The bonus promotion was withdrawn. Production was reduced, and the company began clearing the excess inventory.
More importantly, the company introduced four-monthly Comprehensive Data Analysis reviews for all major brands.
For Mala Gupte, the episode became a defining lesson in her career.
Years later, she would often tell young brand managers:
“Sales numbers can make you happy. But prescriptions, market data, and inventory tell you the truth.”
Core Lesson: Sales growth alone does not always indicate real demand.
Managers must analyze multiple sources of data together before making major decisions.
Hidden Insight
The real issue in the case was not the promotion itself.
The deeper issue was decision-making based on incomplete information.
Discussion Questions
- Why did the Brandex promotion initially appear successful?
- Which warning signals did the company ignore?
- How did reliance on one data source distort decision-making?
- What actions should management take immediately?
- How can companies build a robust CDA system?
Closing Parable – The Brand Manager Who Celebrated Too Early
Mala Gupte looked at the rising sales chart of Brandex at V & V Pharmaceuticals and smiled. The numbers looked impressive, and the team celebrated the success.
Weeks later another report arrived. Doctors were prescribing the brand less, and pharmacies were full of unsold stock. The sales growth had been caused by retailers buying extra stock to gain the bonus offer.
Mala learned a lesson she never forgot.
Numbers can speak loudly. But only when all the numbers speak together do they tell the truth.